Overall, 2019 was a good recovery year for the US Joint Fluid market with Single-injection treatment options at the helm
For Q419, revenue in the US Joint Fluid market was up, recovering fairly well from a year ago according to SmartTRAK Financial Dashboard. Aggregate growth for the quarter was attributable to a double-digit revenue growth in single injection. Stronger demand and heavy product push in that segment, especially at year-end, was offset to a certain extent by revenue declines in 3- and 5-injections.
Among the many topics covered in the comprehensive Q419 US Joint Fluid Market Recap* are:
- Comprehensive Market Overview
- Single-Injection: Reigning as King of The Hill
- 3-Injection: The Victors and The Vanquished
- 5-Injection – Downward Spiral With No End In Site
- 2020: A Look Ahead
For FY19, the US Joint Fluid market appears to have bounced back somewhat from a rough year in 2018 but not quite back to the level of performance seen in 2017. According to SmartTRAK Financial Dashboard, revenue finished at $, up YoY and slightly above forecast. Though marginal, the overall revenue growth of the US Joint Fluid market for FY19 is attributed to a strong year-end push in product placement and to and to several competitors securing preferred formulary status with major commercial health insurance providers, while others simply used smart contracting.